New insider activity at GeoVax Labs ( (GOVX) ) has taken place on April 2, 2025.
President & CEO David Dodd has made a significant investment in GeoVax Labs by purchasing 10,000 shares of the company’s stock. This transaction, valued at $10,800, underscores his confidence in the company’s future prospects.
Recent Updates on GOVX stock
GeoVax Labs, Inc. has recently reported its Q4 earnings, revealing both significant advancements and challenges. The company secured a $400 million award from BARDA for its GEO-CM04S1 COVID-19 vaccine, which is progressing into a Phase 2b trial, and reported promising results from its Phase 2 trials for its COVID-19 booster vaccine. Additionally, GeoVax is advancing its GEO-MVA vaccine platform for Mpox and Smallpox and preparing for a Phase 2 trial of its Gedeptin therapy for head and neck cancer. However, the company faced financial challenges, reporting a net loss of $25 million for 2024, largely due to increased R&D spending and manufacturing costs associated with the BARDA contract. Cash balances decreased to $5.5 million, highlighting financial strain. Delays in the Gedeptin trial due to manufacturing issues also posed setbacks. Despite these hurdles, GeoVax remains focused on expanding its clinical programs and seeks strategic partnerships to enhance its global impact, with an optimistic outlook for 2025.
More about GeoVax Labs
YTD Price Performance: -57.26%
Average Trading Volume: 621,954
Technical Sentiment Signal: Buy
Current Market Cap: $14.67M